Back
Halozyme Therapeutics Stock Price Chart
This Tech Company Grew 32,481%...
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
62
HALO
Halozyme Therapeutics
Last Price:
$57.79
Seasonality Move:
-2.44%
7 Day Trial
ALL ACCESS PASS
$
7
-
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.
Halozyme Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 57.15 | Buy |
| 20-day SMA: | 54.7 | Buy |
| 50-day SMA: | 55.19 | Buy |
| 200-day SMA: | 55.39 | Buy |
| 8-day EMA: | 49.72 | Buy |
| 20-day EMA: | 31.55 | Buy |
| 50-day EMA: | 15.67 | Buy |
| 200-day EMA: | 4.4 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 15.95 | Buy |
| Relative Strength Index (14 RSI): | 61.94 | Buy |
| Chaikin Money Flow: | -583288 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (52.59 - 56.47) | Buy |
| Bollinger Bands (100): | (53.58 - 62.32) | Sell |
Halozyme Therapeutics Technical Analysis
| Jul 3 | Jul 7 | Jul 8 | Jul 9 | Jul 10 | Jul 11 | Jul 14 | Jul 15 | Jul 16 | Jul 17 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul | ||||||||||
| 03 | 07 | 08 | 09 | 10 | 11 | 14 | 15 | 16 | 17 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 57.81 while HALO 8-day simple moving average is 57.15, which is a Buy signal.
-
The stock price of HALO is 57.81 while Halozyme Therapeutics 20-day SMA is 54.70, which makes it a Buy.
-
Halozyme Therapeutics 50-day simple moving average is 55.19 while HALO share price is 57.81, making it a Buy technically.
-
HALO stock price is 57.81 and Halozyme Therapeutics 200-day simple moving average is 55.39, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
62
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a BuyThe current Halozyme Therapeutics [HALO] share price is $57.81. The Score for HALO is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.1B
Price in USD:
57.81
Share Volume:
1.1M
Halozyme Therapeutics 52-Week Range
52-Week High:
70.51
52-Week Low:
42.01
Buy
62
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?The Halozyme Therapeutics stock price is 57.81 USD today.
-
Will HALO stock go up or go down?Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Halozyme Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
-
Halozyme Therapeutics share price is 57.81 while HALO 8-day exponential moving average is 49.72, which is a Buy signal.
-
The stock price of HALO is 57.81 while Halozyme Therapeutics 20-day EMA is 31.55, which makes it a Buy.
-
Halozyme Therapeutics 50-day exponential moving average is 15.67 while HALO share price is 57.81, making it a Buy technically.
-
HALO stock price is 57.81 and Halozyme Therapeutics 200-day simple moving average is 4.40, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.44 per share, an increase next quarter of $0.06 per share, an increase this year of $1.27 per share, and an increase next year of $1.48 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
-
HALO Moving Average Covergence Divergence (MACD) indicator is 15.95, suggesting Halozyme Therapeutics is a Buy
-
Halozyme Therapeutics Relative Strength Index (RSI) is 61.94, which suggest Halozyme Therapeutics is overbought
-
The Bollinger Bands (25) for Halozyme Therapeutics is (52.59 - 56.47), which suggest Halozyme Therapeutics is a Sell
-
The Bollinger Bands (100) for Halozyme Therapeutics is (53.58 - 62.32), which suggest Halozyme Therapeutics is a Sell
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.